Sepsis is associated with systemic inflammation, coagulopathy, and disrupted protein C (PC) pathway function. The effect of prothrombotic polymorphism, factor V Leiden (R506Q) (FV Leiden), was examined in a large clinical trial (PROWESS) of severe sepsis and a mouse endotoxemia model. In PROWESS, 4.1% (n=65) of patients were heterozygous FV Leiden (VL+/-) carriers. The 28-day mortality was lower in VL+/-(13.9%) than in non-FV Leiden (VL-/-) (27.9%) patients (P=0.013). The mortality benefit of recombinant human activated PC (rhAPC) treatment was similar in VL+/-(placebo:15.6%; rhAPC:12.1%) and VL-/-patients (placebo:31.0%; rhAPC:24.7%) (interaction P=0.981). VL+/-status did not appear to influence baseline biomarkers of coagulopathy and inflammation or disease severity, with exception that vasopressor usage was less in VL+/-patients (46.2% vs 63.0 %; P=0.009). In an LD 50 (40mg/kg) endotoxin mouse model, VL+/-mice had lower mortality than wild type mice (19% vs 57%; P=0.008), while mortality of homozygous (VL+/+) mice was almost identical to that of wild type mice (65% vs 57%; P=0.76). The findings suggest that FV Leiden constitutes a rare example of a balanced gene polymorphism that maintains the FV Leiden mutation in the general gene pool due to a survival advantage of VL+/-in severe sepsis.
Introduction
Coagulation activation and inflammation are both parts of the innate host response to infection that may contribute to organ dysfunction and death when control of these systems is compromised. 1, 2 The PC pathway suppresses excessive activation of blood coagulation and protects against inadvertent blood clots by inactivation of coagulation factors Va and VIIIa.
For personal use only. on November 16, 2017 . by guest www.bloodjournal.org From Three independent point mutations in factor V (R506Q, FV Leiden; R306T, FV Cambridge, and R306G, FV Hong Kong) disrupt the activity of this natural anticoagulant pathway by rendering Factor Va partially resistant to inactivation by activated protein C (APC). Despite increasing the risk of thrombosis in heterozygous and homozygous carriers, 3 the FV Leiden allele is highly prevalent in the Caucasian population with an incidence between 4 and 6%. 4, 5 While FV Cambridge is very rare, the FV Hong Kong allele, which is associated with uncertain thrombotic risk, 6, 7 is present in about 3 to 5% of Southeastern Asians. 8, 9 The relatively high prevalence of FV Hong Kong and FV Leiden has prompted speculation about an associated survival advantage exerting a positive selection pressure, 10, 11 for example by reducing blood loss during childbirth or by enhancing -via some unknown mechanismembryo implantation.
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Here we examine the hypothesis that the FV Leiden mutation confers a survival advantage in severe sepsis. This hypothesis is based on several observations. First, animal studies have
shown that natural anticoagulants, in particular the components of the PC pathway (e.g. thrombomodulin (TM) and PC/APC), can reduce mortality associated with septic shock. 15, 16 Second, a recent large clinical trial (PROWESS) demonstrated that treatment with recombinant human APC reduced relative all-cause 28-day mortality by 19.4% in patients with severe sepsis as compared to placebo-treated patients. 17 Third, although a study of 184
in-hospital patients with meningococcemia found increased morbidity in heterozygous FV Leiden carriers, there was a trend towards reduced mortality in FV Leiden carriers compared to non-carriers. 18 Fourth, infusion of low concentrations of thrombin in dogs significantly protected the animals from endotoxin-induced mortality. 19 The infused thrombin likely resulted in augmented activation of endogenous PC by the TM-thrombin complex, thus
For personal use only. on November 16, 2017 . by guest www.bloodjournal.org From potentially increasing endogenous APC levels. Fifth, both antithrombin III and tissue-factorpathway-inhibitor failed to demonstrate a significant reduction in 28-day mortality in phase 3 clinical trials. 20, 21 Potentially these compounds may have prevented the generation of APC from its zymogen, either by inhibiting the active site of thrombin or by preventing the generation of thrombin. These data taken together suggest that mutations that enhance thrombin formation, such as FV Leiden, might have a similar beneficial effect on survival in sepsis, due to augmentation of endogenous PC activation.
An alternative hypothesis is that FV Leiden mutation is detrimental to patients with severe sepsis. It is believed that the consequence of an exaggerated and uncontrolled systemic host inflammation and coagulation (increased thrombin generation) response to the infecting pathogen(s) may lead to microvascular thrombosis, multiple organ dysfunction syndrome and death in severe sepsis. 2, 22 Thrombin is a multi-functional protein that causes endothelial cell perturbation as well as thrombosis. The presence of the prothrombotic FV Leiden mutation, together with a loss of TM function due to endothelial damage in severe sepsis, 23 may result in increased thrombin generation, microvascular thrombosis and tissue injury. These changes could result in higher morbidity, as seen in the study of patients with meningococcemia, 18 and/or higher mortality.
This study employs FV Leiden mutation as a tool for addressing the question of whether thrombin generation in sepsis is beneficial (e.g., via increased APC generation), or detrimental (e.g., via increased microvascular thrombosis and worsened multi-organ dysfunction). Here, by 1) analyzing the effect of FV Leiden carrier status on mortality in a large clinical study on the efficacy of recombinant human APC in the treatment of severe 
Methods
Clinical study in patients with severe sepsis PROWESS was a randomized, double-blind, placebo-controlled phase 3 trial evaluating the efficacy of recombinant human APC (drotrecogin alfa [activated]; Xigris ) in severe sepsis.
The primary efficacy endpoint was 28-day all-cause mortality. Details of the trial design including inclusion and exclusion criteria were previously reported. 17 The study was conducted in 164 hospitals in 11 countries (Australia, Belgium, Brazil, Canada, Germany, 
Measurement of endogenous levels of APC in placebo-treated patients:
Three to seven blood samples were collected from placebo-treated patients enrolled in North America in the PROWESS study for the measurement of endogenous APC levels over the first 4 study days.
Details of the sampling time, sampling method, and assay methodology have been published. 25 The lower limit of quantification of the immuno-capture assay for APC was 10 ng/mL.
Measurement of coagulation and inflammation biomarkers:
Serial blood samples were drawn pre-infusion and on Days 1-7 after start of study drug infusion. All biomarkers except IL-6 levels were determined at each time point from citrated plasma. IL-6 levels were determined from serum. Citrated plasma and serum samples were stored at -70°C until analyzed centrally. were maintained on a C57BL/6 genetic background and are as previously described. [26] [27] [28] In this study we used TMPro mice that were homozygous for the Glu404Pro mutation. Age and sex matched littermate mice derived from heterozygotic (VL+/-) matings were used for all experiments. Genotyping was performed as previously described using a multiplex PCR technique.
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For personal use only. on November 16, 2017 . by guest www.bloodjournal.org From Enzyme Capture Assay for APC: Since no assay for analysis of mouse APC is currently available, the potential for activation of endogenous PC was estimated by infusing human PC and measuring its conversion to APC. In vivo levels of APC were determined using a previously described enzyme capture assay. 29 For personal use only. on November 16, 2017 . by guest www.bloodjournal.org From cross-reactivity with mouse antigens as described. 27 Cytokine assays were performed utilizing Quantikine M kits specific for the indicated murine cytokines (R&D Systems, Minneapolis, MN). In all cases the assays were performed according to the manufacturers directions.
Results

FV Leiden carrier status in the PROWESS patient population
Blood samples were obtained from all patients with severe sepsis (defined as patients with a confirmed or clinically suspected infection associated with one or more acute organ dysfunctions) enrolled in the PROWESS study in order to identify the FV mutation carrier status (R506Q as Factor V Leiden, R306T as Factor V Cambridge, and R306G as Factor V Hong Kong). No homozygous FV Leiden patients were found in the PROWESS patient population, which is not inconsistent with the estimated frequency of 0.06-0.25% in the general Caucasian population. 31 The incidence of VL+/-carriers (4.1%; Table 1 ) is consistent with the known incidence in the general population of the countries from which the patients were enrolled. The 65 FV Leiden carriers in the PROWESS study were enrolled from 10 of the 11 participating countries and 44 of the 164 participating study hospitals. Most (61/65) of the patients with the FV Leiden mutation were Caucasians. All four non-Caucasian patients who were carriers of the FV Leiden mutation were enrolled from North America: one had ancestry from the Indian subcontinent, two were of Hispanic descent, and one had African ancestry.
There were only 29 Asian patients (11 Western Asians and 18 East and Southeast Asians) enrolled in the PROWESS study; FV mutation data were available from 27 of these 29
patients. The prevalence of FV Cambridge and Hong Kong 6,9,32 among PROWESS patients was similar to the frequency of these mutations in the general population and by ethnicity (Table 1) . 6, 7, 32, 33 As only three cases of these two mutations (two for heterozygous FV Cambridge and one for heterozygous FV Hong Kong) were found among all the PROWESS patients, no further analysis was performed.
Baseline characteristics by FV Leiden status in PROWESS
Except for a less frequent need of vasopressor treatment at baseline for maintaining blood pressure (also reflected in baseline cardiovascular SOFA score 34 ), VL+/-carriers were not significantly different from non-Leiden patients with respect to baseline clinical disease severity indices, pre-existing conditions, or baseline status of biomarkers of coagulation activation, fibrinolysis, inflammation and endothelial function (Tables 2a,b) . Confidence intervals for these biomarkers were wide and there was no significant imbalance between the two groups of patients. Endogenous APC levels over the first 4 study days in the placebotreated VL+/-carriers were all below the lower limit of quantification (10 ng/mL) of the assay.
Mortality outcome by FV Leiden status in PROWESS
The 28-day mortality rate among VL+/-patients was about half that observed for non-Leiden patients (Table 3a) . Modeling with stepwise logistic regression confirmed that, after adjusting for other important predictors of mortality including age, disease severity (i.e., APACHE II score), and cardiomyopathy as a pre-existing condition, VL+/-patients had a 2.8 times better odds of survival than non-Leiden patients (1. P=0.008 or 0.007). The relative risk of death with recombinant human APC treatment in VL+/-carriers was not significantly different than in non-Leiden patients (Table 3b ) and, using the above model, the odds of survival with recombinant human APC treatment were about 1.3 times that of placebo-treated patients (1.1-1.7; P=0.013). The Breslow-Day interaction P value (0.981) was non-significant, supporting the conclusion that the effect of recombinant human APC therapy was similar in VL+/-and non-Leiden patients. Further, the protective effect of heterozygous FV Leiden polymorphism and the beneficial effect of recombinant human APC therapy appeared to be independent of one another (interaction P=0.974). These observations suggest, but do not prove, that VL+/-carriers derive a similar benefit from treatment with recombinant human APC as non-Leiden patients.
Reduced anticoagulant response of recombinant human APC in FV Leiden carriers
No significant differences in clinically obvious thrombosis were found between VL+/-and non-Leiden patients (placebo and treatment group) during the 28-day study period. No serious bleeding events were reported in any of the VL+/-carriers. Serious bleeding was significantly more frequent in the non-Leiden patients (P= 0.048) and occurred in 1.0% of patients treated with placebo and in 2.3% of patients receiving recombinant human APC.
Recombinant human APC infusion into VL+/-carriers with severe sepsis failed to prolong the APTT and resulted in a less pronounced decrease in plasma D-dimer levels than in nonLeiden patients (Fig. 1a,b) , confirming a reduced anticoagulant effect of recombinant human APC in VL+/-carriers. (Fig. 2) . Mortality of VL+/+ mice was almost identical to that of wild type mice (65% vs 57%, P=0.76). VL+/-mice were significantly more likely to survive than wild type mice (81% vs 43% survival, P=0.008), or VL+/+ mice. VL+/+ and VL+/-mice challenged with 40 mg E.coli endotoxin/kg body weight consistently produced more -thrombin than wild type mice, as deduced from plasma TAT levels (Fig. 3) . The conversion of infused human PC to APC (See Methods) was augmented in LPS-challenged VL+/-and VL+/+ mice, demonstrating that the excess thrombin formed in As reported earlier, TMPro mice challenged with a lower dose of endotoxin (5 mg endotoxin/kg body weight) exhibited higher plasma levels of IL-6 and IL-1 , compared to wild type mice. 27 In contrast, VL+/+ mice subjected to the same treatment exhibit on average lower plasma concentrations of IL-6 and IL-1 than wild type mice. This trend was statistically significant only for IL-6 levels, and was still noticeable, albeit to a lesser extent, in VL+/-mice (Fig. 4) . These findings confirm that the FV Leiden and the TMPro mutations both augment the procoagulant response associated with endotoxemia, but exert opposite effects on APC generation and, depending on the dose of endotoxin, on IL1 and IL-6
For 
Discussion
The combined human and murine data in this report demonstrate that VL+/-carrier status is associated with a survival benefit in severe sepsis in humans, and confers a survival advantage onto mice in LPS-induced endotoxemia. Due to the low frequency of homozygosity (0.06-0.25%) 36 of FV Leiden in the general human population, it was not possible to establish the effect of homozygous carrier status on the outcome of severe sepsis in humans. In the mouse endotoxemia model, homozygous carrier status did not improve survival, suggesting that the FV Leiden polymorphism may be an example of a balancing selection polymorphism in inflammatory disease, where heterozygous carrier status for a polymorphic allele lends a survival advantage over homozygosity for either allele, 37 akin to the classic sickle cell-malaria paradigm.
The endotoxemia model recapitulates only certain aspects of sepsis, and the FV Leiden mutation may affect the progression of septicemia by different or additional mechanisms than those underlying the benefit seen in mice exposed to endotoxin, for example by reducing bacterial dissemination secondary to augmented fibrin deposition around inflammatory foci.
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Yet, the prevalence of the FV Leiden polymorphism among patients enrolled in the PROWESS study was very similar to that of the general population, indicating that human heterozygous carriers of FV Leiden mutations are neither protected from infection and sepsis per se, nor from disease progression into clinically defined severe sepsis.
The clinical trial (PROWESS) and the animal experiments described here were initiated and conducted independently, and neither approach was specifically designed to reveal the mechanism by which the FV Leiden mutation alters the outcome of severe inflammatory
For personal use only. on November 16, 2017. by guest www.bloodjournal.org From disease. The animal experiments were based on the working hypothesis that the protective effect of the FV Leiden mutation might be mediated by enhanced activation of endogenous PC, thus replicating the benefit derived from treatment with exogenous recombinant human APC seen in human patients. We showed that VL+/-mice, and to a greater extent VL+/+ mice, respond to an LPS-induced inflammatory stimulus with augmented thrombin formation, and concomitantly increased activation of protein C. However, thrombin generation and concomitant PC activation was augmented only mildly and transiently in VL+/-mice, as compared to wild type controls. Later on in the course of endotoxemia, i.e., shortly before the onset of mortality in this model, the coagulation response in VL+/-mice was indistinguishable from that in wild type mice. Likewise, human VL+/-carriers with severe sepsis in PROWESS did not exhibit a more intense coagulopathy as compared to non-Leiden patients, and endogenous APC levels remained below 10 ng/mL in the VL+/-carriers receiving placebo over the first 4 days of the study. In independent studies of human patients (with unknown FV Leiden carrier status) prior to and during episodes of severe sepsis and septic shock, endogenous APC levels were likewise only moderately and transiently elevated, and did not parallel the rise in thrombin generation. 23, 25, [39] [40] [41] [42] If the protective effect of the FV Leiden mutation were indeed attributable to enhanced PC activation, this probably occurs in a transitory fashion during the early stage of disease and would not be observed by the time patients progressed to the stage of severe sepsis, when the endogenous capacity for PC activation is substantially impaired secondary to the suppression of TM activity and the consumption of PC. Indeed, the survival advantage seen in study patients might reflect in part a carry-over of a benefit established in an earlier stage of disease, since VL+/-carriers were distinguished from non-Leiden patients already at study A recent study 43 of recombinant human APC effects in a human endotoxemia model provides circumstantial evidence for a common mechanism underlying the benefit of FV Leiden carrier status and of recombinant human APC therapy. Recombinant human APC, given at 24 µg/kg/hr, significantly attenuated the drop in mean arterial blood pressure in healthy subjects challenged with a low dose of endotoxin (2 ng/kg). Likewise, one of the most significant improvements in organ function associated with recombinant human APC treatment in PROWESS was reflected in the cardiovascular SOFA score, due to reduced vasopressor requirement. 44 The diminished need for vasopressor use among FV Leiden
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Taken together, the proposed APC-dependent mechanism of action of the survival benefit of the FV Leiden mutation, while compatible with the presented data, must await stringent experimental verification. Similarly, the reason why the FV Leiden mutation affords protection only in VL+/-, but not in VL+/+ mice subjected to endotoxemia remains unclear.
Since only VL+/+ mice, but not VL+/-or wild type mice exhibit a lasting augmentation of coagulation in the later stage of endotoxemia, it is conceivable that the persistent prothrombotic state may produce more pronounced thrombotic organ damage in VL+/+ mice, which may negate the benefit of any early protective effect. Alternatively, the lack of a survival benefit in VL+/+ mice might be due to the loss of some unknown, potentially coagulation-independent function of the normal FV molecule. Tables   Table 1. Comparison of the incidence of Factor V mutations in the PROWESS a study to the general population.
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